S1 Data for: "Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control Study from Coastal Kenya"

Nyiro, JU, Sande, CJ, Mutunga, M, Kiyuka, PK, Munywoki, PK, Scott, JAGORCID logo and Nokes, DJ (2016). S1 Data for: "Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control Study from Coastal Kenya". [Dataset]. PLOS ONE. https://doi.org/10.1371/journal.pone.0166706.s001
Copy

The target group for severe respiratory syncytial virus (RSV) disease prevention is infants under 6 months of age. Vaccine boosting of antibody titres in pregnant mothers could protect these young infants from severe respiratory syncytial virus (RSV) associated disease. Quantifying protective levels of RSV-specific maternal antibody at birth would inform vaccine development. METHODS: A case control study nested in a birth cohort (2002–07) was conducted in Kilifi, Kenya; where 30 hospitalised cases of RSV-associated severe disease were matched to 60 controls. Participants had a cord blood and 2 subsequent 3-monthly blood samples assayed for RSV-specific neutralising antibody by the plaque reduction neutralisation test (PRNT). Two sample paired t test and conditional logistic regression were used in analyses of log2PRNT titres. RESULTS: The mean RSV log2PRNT titre at birth for cases and controls were not significantly different (P = 0.4) and remained so on age-stratification. Cord blood PRNT titres showed considerable overlap between cases and controls. The odds of RSV disease decreased with increase in log2PRNT cord blood titre. There was a 30% reduction in RSV disease per unit increase in log2PRNT titre (<3months age group) but not significant (P = 0.3). CONCLUSIONS: From this study, there is no strong evidence of protection by maternal RSV specific antibodies from severe RSV disease. Cord antibody levels show wide variation with considerable overlap between cases and controls. It is likely that, there are additional factors to specific PRNT antibody levels which determine susceptibility to severe RSV disease. In addition, higher levels of neutralizing antibody beyond the normal range may be required for protection; which it is hoped can be achieved by a maternal RSV vaccine.

Keywords

Antibodies, Blood, Enzyme-linked immunoassays, Infants, Infectious disease control, Cohort studies, Vaccine development, Vaccines

No files available. Please consult associated links.


Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core (with Type as Type) MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON METS MODS RDF+N3 RDF+N-Triples RDF+XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads